Hinge Health, Inc. (HNGE) AI Stock Analysis

Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. The company designs its platform to address musculoskeletal system care, covering acute injury, chronic pain, and post-surgical rehabilitation. It delivers personalized and automated care by combining AI-powered motion tracking technology with a proprietary electrical nerve stimulation wearable device. Primarily serving self-insured employers, Hinge Health was founded in 2012 and operates from its headquarters in San Francisco, California.

Revenue grew from $292.7M in FY2023 to $390.4M in FY2024 and reached $587.9M in FY2025, representing a two-year revenue CAGR of 41.7%. Gross margin expanded from 66.3% in FY2023 to 77.0% in FY2024 and 79.8% in FY2025. Net income was -$108.1M in FY2023, -$11.9M in FY2024, and -$528.3M in FY2025, impacted by $368.1M in R&D expense. Operating cash flow improved from -$63.9M in FY2023 to $171.4M in FY2025, alongside free cash flow of $170.7M. Over the trailing twelve months ended June 30, 2026, revenue totaled $720.1M, with quarterly revenue rising 53.0% year-over-year while quarterly earnings declined 68.4%.

As of June 30, 2026, Hinge Health held $389.4M in cash and short-term investments alongside total debt of $5.9M, resulting in a net cash position of $383.5M. The company reported a current ratio of 1.34 and a debt-to-equity ratio of 0.02, supported by $344.3M in shareholders' equity and $827.4M in total assets. During FY2025, capital expenditures were $708,000, and the company allocated $65.0M toward share buybacks.

At a share price of $99.16, Hinge Health trades at a trailing P/E of 32.7x and a forward P/E of 33.0x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its enterprise value of $7.06B corresponds to an EV/EBITDA of 71.8x, above the peer median of 12.0x, and a price-to-sales ratio of 11.1x versus the peer median of 4.1x. Over the past year, the stock returned 95.4%, outpacing the S&P 500 return of 16.8%, and currently trades 55.3% above its 200-day moving average.

Wall Street coverage consists of 9 Strong Buy, 7 Buy, and 1 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target of $112.12 represents a 13.1% premium to the last closing price of $99.16. For the fiscal year ending December 31, 2026, analysts estimate revenue of $860.6M and EPS of $2.40. For the following fiscal year, 13 analysts project revenue to reach $1.09B with EPS of $3.06. Hinge Health beat EPS estimates in each of the past 4 quarters, with its next earnings date scheduled for November 2, 2026.

This page is an AI-written research summary of Hinge Health, Inc. (HNGE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HNGE income statement, HNGE balance sheet, HNGE key metrics, HNGE analyst forecast, HNGE chart. See the HNGE stock overview for the latest quote and news.